Loading market movers...

All Therapeutic Areas

🧠

Neurology & CNS

82 drugs in pipeline from 10 companies

82

Drugs in Pipeline

10

Companies

5

Upcoming Catalysts

82

Phase 3 Trials

Upcoming Catalysts

Sep '26

SKBBYPhase 2

PRT-064040 nasal spray Phase 2 Est. Readout

PRT-064040 nasal spray• Migraine456

Sep 2026~ConfirmedSTALE+IMMINENT

00%

Sep '26

ARGXPhase 3$56.5B

✓Positive

IVIG (Intravenous Immunoglobulin) Phase 3 Est. Readout

IVIG (Intravenous Immunoglobulin)• Multifocal Motor Neuropathy (MMN)154

Sep 2026~Confirmed

Sep '26

ALKSPhase 3$7.5B

Olanzapine Phase 3 Est. Readout

ALKS 3831• Schizophrenia220

Sep 2026~ConfirmedSTALE+IMMINENT

00%

Sep '26

RHHBYPhase 2$316.4B

Ocrelizumab Test Formulation Phase 2 Est. Readout

Ocrelizumab Test Formulation• Multiple Sclerosis193

Sep 2026~Confirmed

00%

Sep '26

HSCSWPhase 2

64Cu-FBP8 Phase 2 Est. Readout

64Cu-FBP8• Alzheimer Disease30

Sep 2026~Confirmed

00%

View all catalysts

Pipeline by Phase

Phase 3

82

Active Companies

ASTRAZENECA PLC

Johnson & Johnson

TAKEDA PHARMACEUTICAL CO LTD

Teva Pharmaceutical Industries Limited

Sanofi

HeartSciences Inc.

Hong Kong Pharma Digital Technology Holdings Ltd

Eisai

MYLAN

COGNITION THERAPEUTICS INC

Related Conditions

alzheimerparkinsonmultiple sclerosisepilepsystrokeneuropathydementiamigrainealshuntingtonseizurecnsneurologicalneurodegenerativebrainspinalnerveschizophreniadepressionanxietybipolaradhdautismpsychosisptsdocd